UNITED THERAPEUTICS CORP (UTHR)
US91307C1027 - Common Stock
Halozyme Therapeutics Stock Earns IBD Stock Rating Upgrade, Hitting 80-Plus RS Rating
On Thursday, biotech Halozyme Therapeutics stock had its Relative Strength (RS) Rating upgraded to 84, up from 80 a day earlier.
NASDAQ:UTHR is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
UNITED THERAPEUTICS CORP (NASDAQ:UTHR), an undervalued stock with good fundamentals.
Catalyst Pharmaceuticals Stock Clears Technical Benchmark With 83 RS Rating
On Tuesday, Catalyst Pharmaceuticals stock hit a key technical milestone, with its Relative Strength Rating climbing to 83 from 79.
3 Biotech Stocks to Double Your Money in the Next 24 Months
The biotech sector offers significant potential for growth. These 3 biotech stocks to double your money are noteworthy candidates.
UTHR Stock Earnings: United Therapeutics Beats EPS, Beats Revenue for Q1 2024
UTHR stock results show that United Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
United Therapeutics Corporation Reports First Quarter 2024 Financial Results
CORRECTING and REPLACING PHOTO United Therapeutics Announces World’s First Successful Xenothymokidney Transplant
Noteworthy Wednesday Option Activity: UTHR, ACN, PI
United Therapeutics Corporation to Report First Quarter 2024 Financial Results Before the Market Opens on Wednesday, May 1, 2024
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2024 International Conference
United Therapeutics Announces the First Comprehensive Review Publication on Xenotransplantation
The Bargain Hunter’s Portfolio: 7 Smart Stock Buys for the Shrewd Investor
Although several companies have seen their valuations blossom, you can still find bargain stocks if you know where to look.
Notable Monday Option Activity: WM, POST, UTHR
United Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase Program
The 3 Most Undervalued Nasdaq Stocks to Buy in March 2024
Learn about these undervalued NASDAQ stocks teeming with the potential to bounce back and show great returns for investors this year.
Game Changers: 3 Biotech Stocks That Could Be Multibaggers in the Making
These three companies represent the world of biotech stocks and offer a unique blend of high risk and potentially high reward.
United Therapeutics Corporation to Present at the Leerink Partners Global Biopharma Conference 2024
United Therapeutics Moves Up In Market Cap Rank, Passing Paycom Software
United Therapeutics Corporation to Present at the TD Cowen 44th Annual Health Care Conference
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
Although the health innovation space can be a risky environment, undervalued biotech stocks can take some of the edge off.
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2023 Financial Results
United Therapeutics Commences Litigation to Ensure Fairness in the Drug Review Process
Commit To Buy United Therapeutics At $210, Earn 7.9% Annualized Using Options
United Therapeutics is Now Oversold (UTHR)
Biotech Stocks Are on Fire: Here Are the Top 3 Picks for January
These biotech stocks offer exciting and disruptive solutions with the potential to expand to market caps worth trillions.
Catalyst Countdown: 3 Biotech Stocks With Upcoming News That Could Move the Market
In the volatile world of biotech stocks, keeping an eye on the news is critical. Here are three companies to look out for.
MannKind, Sagard Healthcare enter $200M royalty purchase deal (NASDAQ:MNKD)
MannKind (MNKD) sells a 1% royalty in Tyvaso DPI net sales to Sagard Healthcare for up to $200M, receiving an upfront payment of $150M.